ZURA is registering massive massive volume based on weekly data. Volume net buys have increase two-folds from its average numbers, from 2.3M average volume to 5.7M last trading day. A huge hint of things to come for this stock after a
80M
financing for its Phase 2 clinical trial for ZB-106 in systemic sclerosis (SSc), followed by a Phase 2 clinical trial in hidradenitis suppurativa (HS).
KEY NOTES:
WEEKLY PRICE SHIFT
HISTOGRAM SHIFT
1ST BUBBLE UP VOLUME in 3 months (bottom indicator)
The chart is clean -- even without explaining it, you can DECIDE. :)
Spotted at 7.0
TAYOR.
Safeguard capital always.
----------------------------------------------
FUNDAMENTAL NEWS (Source YT site)
Zura Bio Completes Approximately $80 Million Financing with the Focus on Advancing ZB-106, a Potential First-in-class Anti-IL-17 and Anti-BAFF Dual Antagonist
Total cash and cash equivalents of approximately $120 million is expected to fund planned clinical and operating activities through 2026
SAN DIEGO, June 06, 2023--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: "ZURA") ("Zura Bio"), a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, today announced the final closing of a private placement resulting in gross proceeds to Zura Bio of approximately $80 million. This funding will allow Zura Bio to initiate a Phase 2 clinical trial for ZB-106 in systemic sclerosis (SSc), followed by a Phase 2 clinical trial in hidradenitis suppurativa (HS).
ZB-106 currently has clinical data from two Phase 1b studies completed in rheumatoid arthritis and Sjögren's syndrome. The safety profile to date appears to be acceptable, with no new findings relative to known IL-17 and BAFF inhibitors. Chronic toxicology studies have been completed with no adverse drug-related findings.
"To complete the financing is a key milestone. Not just for Zura Bio as a company, but for the development of our ZB-106 asset and the benefits that we hope it can bring to patients. Achieving our cash targets puts us in a great position to progress important clinical development programs and we are excited to move our operations forward as a result." said Dr. Someit Sidhu, Chief Executive Officer and Director of Zura Bio.
80M
financing for its Phase 2 clinical trial for ZB-106 in systemic sclerosis (SSc), followed by a Phase 2 clinical trial in hidradenitis suppurativa (HS). KEY NOTES:
WEEKLY PRICE SHIFT
HISTOGRAM SHIFT
1ST BUBBLE UP VOLUME in 3 months (bottom indicator)
The chart is clean -- even without explaining it, you can DECIDE. :)
Spotted at 7.0
TAYOR.
Safeguard capital always.
----------------------------------------------
FUNDAMENTAL NEWS (Source YT site)
Zura Bio Completes Approximately $80 Million Financing with the Focus on Advancing ZB-106, a Potential First-in-class Anti-IL-17 and Anti-BAFF Dual Antagonist
Total cash and cash equivalents of approximately $120 million is expected to fund planned clinical and operating activities through 2026
SAN DIEGO, June 06, 2023--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: "ZURA") ("Zura Bio"), a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, today announced the final closing of a private placement resulting in gross proceeds to Zura Bio of approximately $80 million. This funding will allow Zura Bio to initiate a Phase 2 clinical trial for ZB-106 in systemic sclerosis (SSc), followed by a Phase 2 clinical trial in hidradenitis suppurativa (HS).
ZB-106 currently has clinical data from two Phase 1b studies completed in rheumatoid arthritis and Sjögren's syndrome. The safety profile to date appears to be acceptable, with no new findings relative to known IL-17 and BAFF inhibitors. Chronic toxicology studies have been completed with no adverse drug-related findings.
"To complete the financing is a key milestone. Not just for Zura Bio as a company, but for the development of our ZB-106 asset and the benefits that we hope it can bring to patients. Achieving our cash targets puts us in a great position to progress important clinical development programs and we are excited to move our operations forward as a result." said Dr. Someit Sidhu, Chief Executive Officer and Director of Zura Bio.
액티브 트레이드:
+25% so far, more to go.